Chennai: Pfizer sets up Asia’s first global drug development center, will research drug ingredients and ready-made dosages


In a significant move to bring critical R&D capabilities under one roof, pharmaceutical company Pfizer has set up a global drug development center at IIT Madras Research Park in Chennai, Tamil Nadu. There will be research and development of both active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) of products such as complex/value-added formulations, controlled-release dosage forms, device-combination products, lyophilized injections, powders. This will help develop products in global markets and Pfizer’s manufacturing centers around the world.


KS Sridhar, Country Manager, Pfizer India, said that setting up of one of Pfizer’s most advanced laboratories, the Drug Development Center at IIT Madras Research Park, is indeed a positive initiative. We are confident that this will allow co-development of state-of-the-art API and FDF processes under one roof. The world class scientific, technology and innovation driven research park campus provides an ideal location for our work. We hope that proximity to IIT Madras and other technology research park start-ups will also improve academic and industry partnerships and encourage greater collaboration to drive innovation.

Pfizer has invested $20 million (Rs 150 crore) in a 61,000-square-foot research and technology center at IIT Madras Research Park. While the center will be part of a network of 12 global centers set up around the world, it is currently the first and only one being set up by Pfizer in Asia. S Aparna, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers said on the occasion of its launch that there is an increasing need for pharma companies to provide innovative solutions and to address the new challenges faced by healthcare providers and patients.